

IN THE CLAIMS:

1 1. (Cancelled)

1 2. (Currently Amended) The liquid composition method of
2 Claim 4 15, wherein each molecule of said polymer comprises a plurality of blocks,
3 each of which has a cloud point, and at least one hydrophilic block covalently
4 bonded with said plurality of blocks.

1 3. (Currently Amended) The liquid composition method of
2 Claim 2, wherein said plurality of blocks are selected from the group consisting of N-
3 acryloylpiperidine, N-propylmethacrylamide, N-isopropylacrylamide, N-
4 diethylacrylamide, N-isopropylmethacrylamide, N-cyclopropylacrylamide, N-
5 acryloylpyrrolidine, N-ethylmethacrylamide, N-cyclopropylmethacrylamide, N-
6 ethylacrylamide, propyleneoxide, alkeneoxide, vinylmethylether, and partially-
7 acetylated vinyl alcohol.

1 4. (Currently Amended) The liquid composition method of
2 Claim 2, wherein said hydrophilic block is selected from the group consisting of
3 methyl cellulose, dextran, ethyleneoxide, vinyl alcohol, N-vinyl pyrrolidone,
4 vinylpyridine, acrylamide, methacrylamide, N-methylacrylamide,
5 hydroxyethylmethacrylate, hydroxyethylacrylate, hydroxymethylmethacrylate,
6 hydroxymethylacrylate, methacrylicacid, acrylic acid, vinylsulfonic acid,
7 styrenesulfonic acid, N, N-dimethylaminoethylmethacrylate, N, N-diethylaminoethyl
8 methacrylate, and N, N-dimethylaminopropylacrylamide.,

1 5. (Currently Amended) The liquid composition method of
2 Claim 4 15, wherein said transition temperature is between 0°C and 40°C.

1 6. (Currently Amended) The liquid composition method of
2 Claim 4 15 further comprising adding biologically active substances to said organic
3 polymer.

1 7. (Currently Amended) The liquid composition method of
2 Claim 6, wherein the biologically active substances are selected from the group
3 consisting of cytokines and extracellular matrix materials.

1 8. (Currently Amended) The liquid composition method of
2 Claim 7, wherein the cytokines are selected from the group consisting of tumor
3 growth factor, fibroblast growth factor, vascular endothelial growth factor and
4 platelet-derived growth factor.

1 9. (Currently Amended) The liquid composition method of
2 Claim 7, wherein the extracellular matrix materials are selected from the group
3 consisting of collagen, gelatin, fibronectin, vitronectin, laminin, proteoglycan, and
4 glycosaminoglycan.

1 10. (Currently Amended) The liquid composition method of
2 Claim 6, wherein the biologically active substances further comprise antineoplastic
3 agents.

1 11. (Currently Amended) The liquid composition method of
2 Claim 4 15 further comprising adding radiopaque agents to said organic polymer.

1 12. (Currently Amended) The liquid composition method of
2 Claim 11, wherein the radiopaque agents are selected from the group consisting of
3 powdered tungsten, powdered tantalum, powdered gold, powdered platinum,
4 barium sulfate and organoiodine compounds. .

1 13. (Currently Amended) The liquid composition method of
2 Claim 4 15, wherein said organic polymer further comprising comprises substances
3 which alter the gel-sol transition temperature.

1 14. (Currently Amended) The liquid composition method of
2 Claim 4 15, wherein said organic polymer further comprising comprises substances
3 which alter viscosity of the aqueous solution.

1 15. (Original) A method for occluding a vascular lumen
2 comprising the step of injecting into said lumen an aqueous solution of an organic
3 polymer having a gel-sol transition temperature wherein said aqueous solution
4 forms a hydrogel at temperatures above said transition temperature.

16. (Cancelled)